Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Panel Offers Specifics For Revised CAP Trial Guidance, No Big Changes

Executive Summary

Design of trials for community-acquired pneumonia drugs would face greater specificity but no major changes according to recommendations from FDA's Anti-Infective Drugs Advisory Committee

You may also be interested in...



Pneumonia Guidances Revisited: FDA Cmte. To Weigh Study Design Issues Again

FDA’s Anti-Infective Drugs Advisory Committee will take its third look in less than four years at standards for developing antibacterial agents to treat community-acquired bacterial pneumonia, at a meeting on Nov. 3.

Pneumonia Guidances Revisited: FDA Cmte. To Weigh Study Design Issues Again

FDA’s Anti-Infective Drugs Advisory Committee will take its third look in less than four years at standards for developing antibacterial agents to treat community-acquired bacterial pneumonia, at a meeting on Nov. 3.

CAP Drugs Must Meet Stricter Noninferiority Criteria Under Draft FDA Guidance

Biopharma firms developing drugs to treat community acquired pneumonia would be wise to follow the specifications FDA has set forth in a new 1draft guidance on the subject. The guidance specifies strict criteria for patient selection and confirmation of infection to support an evaluation based on noninferiority margins

Related Content

UsernamePublicRestriction

Register

PS049479

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel